Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 3/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4879969 | 0.98 | PLA2G2C (0.32) | PLA2G2CTRPM8MMP1MMP2MMP3 | |
| SCHEMBL2834718 | 0.95 | MMP1 (0.32) | PLA2G2CTRPM8MMP1MMP2MMP3 | |
| SCHEMBL1039032 | 0.87 | PPARD (0.32) | MMP1MMP2MMP3 | |
| SCHEMBL16427895 | 0.84 | LPAR3 (0.50) | TRPM8LPAR3LPAR2CETPSMPD1 | |
| SCHEMBL11649168 | 0.84 | LPAR3 (0.50) | TRPM8LPAR3LPAR2CETPSMPD1 | |
| SCHEMBL14890431 | 0.84 | LPAR3 (0.50) | TRPM8LPAR3LPAR2CETPSMPD1 | |
| SCHEMBL17644499 | 0.84 | PPARD (0.38) | PLA2G2CTRPM8MMP1MMP2MMP3 | |
| SCHEMBL10799957 | 0.84 | LPAR3 (0.50) | TRPM8LPAR3LPAR2CETPSMPD1 | |
| SCHEMBL2150294 | 0.84 | LPAR3 (0.50) | TRPM8LPAR3LPAR2CETPSMPD1 | |
| SCHEMBL2184552 | 0.84 | LPAR3 (0.50) | TRPM8LPAR3LPAR2CETPSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567513-A | Self-assembled monolayer hole transport material containing bisphosphonic acid terminal group, preparation method and application | 南开大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-1904479-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
| US-20050026873-A1 | Type-I methionyl aminopeptidases inhibitors in antibacterial targeting | UTAH STATE UNIVERSITY | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026873-A1 | Type-I methionyl aminopeptidases inhibitors in antibacterial targeting | METAP1, METAP2, DNPEP | PLA2G2C 944/4885TRPM8 1650/4885MMP1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.